Form 8-K

8-K — AETHLON MEDICAL INC

Accession: 0001683168-26-006344

Filed: 2026-08-13

Period: 2026-08-13

CIK: 0000882291

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — aethlon_8k.htm (Primary)

EX-99.1 — PRESS RELEASE (aethlon_ex9901.htm)

GRAPHIC (image_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: aethlon_8k.htm · Sequence: 1

AETHLON MEDICAL, INC. 8-K

false

0000882291

2026-08-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 13, 2026

Aethlon

Medical, Inc.

(Exact name of registrant as specified in its

charter)

Nevada

001-37487

13-3632859

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer Identification No.)

11555

Sorrento Valley Road, Suite

203

San Diego, California

92121

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (619) 941-0360

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

AEMD

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

The information provided below in “Item 7.01 - Regulation FD

Disclosure” of this Current Report on Form 8-K (this “Current Report”) is incorporated by reference into this Item 2.02.

Item

7.01 Regulation FD Disclosure.

On August 13, 2026, Aethlon

Medical, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended June 30, 2026.

A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information set forth

under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to

the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated

by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference

language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed

an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements

and Exhibits.

(d) Exhibits

Exhibit Number

Description

99.1

Press Release, dated August 13, 2026

104

Cover Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the

registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 13, 2026

AETHLON MEDICAL, INC.

By:

/s/ James B. Frakes

Name:

Title:

James B. Frakes

Chief Executive Officer and Chief Financial Officer

EX-99.1 — PRESS RELEASE

EX-99.1

Filename: aethlon_ex9901.htm · Sequence: 2

Exhibit 99.1

Aethlon Medical Reports

Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program

Conference Call Today at 4:30 p.m. ET

SAN DIEGO, August 13, 2026 -- Aethlon

Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results

for fiscal first quarter ended June 30, 2026, and provided a corporate update.

“We advanced our clinical and research programs during the quarter,”

said James Frakes, CEO and CFO. “We treated the first participant in the third and final dosing cohort of our Phase 1 oncology study

in Australia, and early biomarker signals from the initial cohorts support continuing evaluation of the Hemopurifier. We also had a Long

COVID manuscript accepted for publication, which strengthens the scientific case for studying extracellular vesicles in post-viral conditions.”

Clinical highlights

· Phase 1 oncology study: First participant

dosed in the third and final cohort in Australia. Early observations from the first two cohorts showed consistent decreases in tumor-derived

extracellular vesicles and microRNAs linked to cancer progression and improvements in immune fumction associated with potential response

to immunotherapy. These observations are preliminary and will be evaluated fully after study completion.

· Long COVID publication: A manuscript describing

extracellular vesicle characteristics in patients with Long COVID was accepted for publication in the International Journal of Molecular

Sciences. The manuscript demonstrates that the extracellular vesicles isolated from the plasma of individuals with Long COVID bind

to the proprietary GNA affinity resin in the Hemopurifier.

Financial highlights

· Cash and liquidity: Cash and cash equivalents

were approximately $4.9 million as of June 30, 2026.

· Post-quarter financing: Subsequent to quarter-end,

Aethlon raised approximately $4.0 million in gross proceeds through a public offering of common stock. Based on current plans, the company

believes its cash resources are sufficient to fund operations for at least the next 12 months.

· Operating expenses: Consolidated operating expenses

for the quarter decreased 11.9% to approximately $1.6 million versus $1.8 million in the prior-year quarter, driven by lower professional

fees and reduced general and administrative and preclinical research costs. Operating loss declined accordingly.

The consolidated balance sheets for June 30, 2026,

and March 31, 2026 and the consolidated statements of operations for the fiscal quarters ended June 30, 2026, and 2025, are included at

the end of this release.

Conference Call

Management will host a conference call today, Thursday,

August 13, 2026, at 4:30 p.m. ET to review the Company’s financial results and recent corporate developments. Following management’s

formal remarks, there will be a question-and-answer session.

Interested parties can register for the conference

call by navigating to https://dpregister.com/sreg/10211144/104a3acc428. Please note that registered

participants will receive their dial-in number upon registration.

Interested parties without internet access or unable

to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741

PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

All callers should ask for the Aethlon Medical, Inc.

conference call.

A replay of the call will be available approximately

one hour after the end of the call through September 13, 2026. The replay can be accessed via Aethlon Medical’s website or by dialing

1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number

is 6711524.

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical

device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally

with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich

surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies

and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both in vitro studies and human subjects.

The Hemopurifier holds a U.S. Food and Drug Administration

Breakthrough Device Designation for:

The treatment of individuals with advanced or metastatic

cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved

therapies.

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage

medical therapeutic company headquartered in San Diego, California. The Company is advancing the Hemopurifier®, an investigational

extracorporeal immunotherapeutic platform designed to remove tumor-derived extracellular vesicles and enveloped viruses from circulation

for potential applications in oncology, infectious disease, and other disease states.

For more information, visit www.AethlonMedical.com

and follow the Company on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements

within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks

and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect,"

"intend," "plan," "project," "will," "projections," "estimate," "potentially"

or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, among others, statements

regarding: the investigational status and potential safety, feasibility, or utility of the Hemopurifier®; the Company’s ability

to initiate, enroll, conduct, and complete its clinical trials, including in Australia; the timing, scope, design, and potential outcomes

or interpretation of such studies; the Company’s ability to manufacture the Hemopurifier in sufficient quantities for clinical and

potential future commercial use; the availability and adequacy of capital to support ongoing operations; statements regarding the Company’s

Ebola-related compassionate use activities and any resulting interest from public health organizations; the Company’s collaborative

research activities, including rheumatoid arthritis, chronic kidney disease, and other extracellular vesicle- associated conditions; and

the Company’s ability to advance or expand its research programs in oncology, infectious diseases, and other conditions associated

with extracellular vesicles. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may

differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's

current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such

differences include, without limitation, the fact that the cash on hand may not be sufficient to support operations for the next 12 months

without additional financing, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company’s

ability to successfully complete development of the Hemopurifier; the Company’s ability to successfully demonstrate the utility

and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company’s ability to achieve

and realize the anticipated benefits from operational and financial milestones; the Company’s ability to maintain its Nasdaq listing,

the Company’s ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline

expected by the Company; the Company’s ability to enroll additional patients in its oncology clinical trial in Australia, including

on the timeline expected by the Company; the Company’s ability to manage and successfully complete its clinical trials; the Company’s

ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory

requirements; the Company’s collaborative research with UCSF Long Covid Clinic; and the Company’s ability to further research

potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and

uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated

in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for

the year ended March 31, 2026, and in the Company's other filings with the Securities and Exchange Commission, including its Quarterly

Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made.

Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future

events or circumstances. Because the Hemopurifier® is an investigational device, its safety and effectiveness have not been established,

and no conclusions should be drawn regarding clinical benefit. The observations contained in this release are from an early feasibility

study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters.

Company

Contact:

Jim Frakes

Chief Executive Officer and Chief Financial Officer

Aethlon Medical, Inc.

Jfrakes@aethlonmedical.com

Investor Contact:

Susan Noonan

S.A. Noonan Communications, LLC

susan@sanoonan.com

AETHLON MEDICAL, INC. AND SUBSIDIARY

Condensed Consolidated Balance Sheets

June 30, 2026

(Unaudited)

March 31, 2026

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$ 4,933,579

$ 5,026,458

Deferred offering costs

394,192

210,985

Prepaid expenses and other current assets

283,143

332,094

TOTAL CURRENT ASSETS

5,610,914

5,569,537

Property and equipment, net

293,112

356,822

Operating lease right-of-use asset, net

232,195

307,820

Restricted cash

99,150

98,928

TOTAL ASSETS

$ 6,235,371

$ 6,333,107

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts payable

$ 411,373

$ 384,550

Due to related parties

68,250

Operating lease liability, current portion

255,052

336,718

Other current liabilities

301,367

657,317

TOTAL LIABILITIES, ALL CURRENT

1,036,042

1,446,835

STOCKHOLDERS' EQUITY

Common stock, $0.001 par value; 20,000,000 shares authorized as of June 30, 2026 and March 31, 2026; 477,402 shares issued and outstanding as of June 30, 2026 and 314,100 shares issued and outstanding at March 31, 2026

477

314

Additional paid-in capital

181,891,939

180,024,947

Accumulated other comprehensive loss

(38,889 )

(32,703 )

Accumulated deficit

(176,654,198 )

(175,106,286 )

TOTAL STOCKHOLDERS' EQUITY

5,199,329

4,886,272

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$ 6,235,371

$ 6,333,107

AETHLON MEDICAL, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Operations and Comprehensive Loss

For the three months ended June 30, 2026 and 2025

(Unaudited)

Three Months

Ended

June 30, 2026

June 30, 2025

OPERATING EXPENSES

Professional fees

$ 333,569

$ 476,032

Payroll and related expenses

583,183

581,000

General and administrative

662,450

735,358

Total operating expenses

1,579,202

1,792,390

OPERATING LOSS

(1,579,202 )

(1,792,390 )

Interest income, net

31,290

30,532

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

(1,547,912 )

(1,761,858 )

OTHER COMPREHENSIVE LOSS

(6,186 )

(5,244 )

COMPREHENSIVE LOSS

$ (1,554,098 )

$ (1,767,102 )

Basic and diluted net loss per share attributable to common stockholders

$ (4.02 )

$ (42.42 )

Weighted average number of common shares outstanding - basic and diluted

384,705

41,529

GRAPHIC

Filename: image_001.jpg · Sequence: 6

Binary file (16545 bytes)

Download image_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 13, 2026

Entity File Number

001-37487

Entity Registrant Name

Aethlon

Medical, Inc.

Entity Central Index Key

0000882291

Entity Tax Identification Number

13-3632859

Entity Incorporation, State or Country Code

Entity Address, Address Line One

11555

Sorrento Valley Road

Entity Address, Address Line Two

Suite

203

Entity Address, City or Town

San Diego

Entity Address, State or Province

Entity Address, Postal Zip Code

92121

City Area Code

619

Local Phone Number

941-0360

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value per share

Trading Symbol

AEMD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration